Roth Mkm Begins Coverage on Reviva Pharmaceuticals (NASDAQ:RVPH)

Stock analysts at Roth Mkm started coverage on shares of Reviva Pharmaceuticals (NASDAQ:RVPH) in a note issued to investors on Friday,Benzinga reports. The brokerage set a “buy” rating and a $7.00 price target on the stock. Roth Mkm’s price target suggests a potential upside of 272.34% from the company’s previous close.

Separately, EF Hutton Acquisition Co. I raised shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research report on Monday, September 23rd. Four analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $11.25.

Reviva Pharmaceuticals Stock Up 0.5 %

RVPH opened at $1.88 on Friday. Reviva Pharmaceuticals has a 52-week low of $0.60 and a 52-week high of $4.83. The company has a 50 day moving average of $1.56 and a two-hundred day moving average of $1.29. The company has a market cap of $62.87 million, a P/E ratio of -1.69 and a beta of -0.12.

Hedge Funds Weigh In On Reviva Pharmaceuticals

A hedge fund recently raised its stake in Reviva Pharmaceuticals stock. Geode Capital Management LLC raised its holdings in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 17.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 278,496 shares of the company’s stock after acquiring an additional 42,376 shares during the quarter. Geode Capital Management LLC owned 0.83% of Reviva Pharmaceuticals worth $401,000 as of its most recent filing with the Securities and Exchange Commission. 63.18% of the stock is owned by hedge funds and other institutional investors.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.